Mechanism of action:
Doluvir(Dolutegravir) is an HIV-1 antiviral agent. It inhibits HIV integrase by binding to the active site and blocking the strand transfer step to retroviral DNA integration. This is an essential step of the HIV replication cycle and will result in an inhibition of viral activity.
Dosage and Administration:
Doluvir(Dolutegravir) exactly as your healthcare provider tells you to.
- Treatment naive or treatment experienced INSTI-naive: 50mg once daily.
- Treatment-Naive or Treatment INSTI-naïve when coadministered with certain UGT1A or CYP3A inducers: 50mg twice daily.
- INSTI-Experienced with certain INSTI-associated resistence Substitution or clinically Suspected INSTI Resistence: 50mg two times in a day.
Coadministration with dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events.
Hypersensitivity reactions reported; characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury.Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations.Redistribution/accu
The most common adverse reactions with Doluvir were headache and fatigue and when used with RBV in decompensated cirrhotics were fatigue,Hypersensitivity reactions,Effects on serum liver biochemistries in patients with hepatitis B or C,co-infection,Fat Redistribution,Immune Reconstitution Syndrome,Trouble sleeping,Tiredness.